UPDATE : Thursday, October 17, 2019
Regulator, Kolon rebuked for slow response to Invossa problem by Jeong Sae-im 2019-04-11 14:46
Canada OKs Celltrion’s Truxima by Lee Han-soo 2019-04-11 11:33
Patients may file class-action lawsuit against Kolon for mislabeling Invossa by Jeong Sae-im 2019-04-10 14:41
Celltrion, iProgen to co-develop novel antibody-drug conjugates by Lee Han-soo 2019-04-09 16:04
Kolon’s foreign partners await cell analysis results by Jeong Sae-im 2019-04-08 14:28
Kolon Life Science criticized for poor quality control on Invossa by Jeong Sae-im 2019-04-05 12:27
‘Invossa, first treatment to have used cancerous cell lines’ by Jeong Sae-im 2019-04-04 15:24
Celltrion completes patient registration for Humira biosimilar by Lee Han-soo 2019-03-28 18:04
Alteogen wins patent on SC injection formulation for Herceptin biosimilar by Lee Han-soo 2019-03-28 15:04
GC’s US branch opens new plasma collection centers by Lee Han-soo 2019-03-27 10:43
Celltrion licenses out hypertrophic cardiomyopathy treatment to Japan by Lee Han-soo 2019-03-25 15:41
Regulator OKs Medipost’s P1 trial of knee osteoarthritis treatment by Lee Han-soo 2019-03-22 14:22
Samsung Bioepis unveils 3-year follow-up data for Ontruzant by Lee Han-soo 2019-03-22 14:05
'US sales of Truxima imminent' by Jeong Sae-im 2019-03-20 17:59
Samsung BioLogics, Eutilex to develop anti-cancer immunotherapies by Lee Han-soo 2019-03-20 17:18
Samsung Bioepis nullifies patents related to Herceptin in Korea by Lee Han-soo 2019-03-18 15:51
Thea, OliX to cooperate in developing age-related macular degeneration treatment by Lee Han-soo 2019-03-18 12:02
CHA Biotech revises separate operating profit to a loss in 2018 by Jeong Sae-im 2019-03-15 16:26
'OliX to target global market with RNA technology' by Lee Han-soo 2019-03-15 11:44
Loss-making Medipost seeks to avoid administrative issue designation by Jeong Sae-im 2019-03-14 14:33
Back to Top